%0 Journal Article
%T Clinical efficacy of teriflunomide over a fixed 2
%A Julia Morawski
%A Karthinathan Thangavelu
%A Mark S Freedman
%J Multiple Sclerosis Journal
%@ 2055-2173
%D 2018
%R 10.1177/2055217318775236
%X Patients enrolled in the phase 3 TOWER study (NCT00751881) of teriflunomide had variable treatment durations (48¨C173 weeks). This has led to challenges when interpreting results in the context of other phase 3 trials of disease-modifying therapies for multiple sclerosis, which typically have a fixed 2-year duration. This communication reports clinical outcomes in TOWER over a fixed 2-year period. Reductions in annualised relapse rates and 12-week confirmed disability worsening associated with teriflunomide were comparable between overall intent-to-treat and fixed 2-year study populations in TOWER. Consistency in outcomes supports the inclusion of TOWER data in comparative analyses with other disease-modifying therapies. ClinicalTrials.gov: NCT00751881
%K Teriflunomide
%K multiple sclerosis
%K clinical trial
%K phase 3
%K disease-modifying therapy
%K outcomes assessment
%U https://journals.sagepub.com/doi/full/10.1177/2055217318775236